Comparison of Coronary Flow Reserve and Fractional Flow Reserve in Patients With Versus Without Diabetes Mellitus and Having Elective Percutaneous Coronary Intervention and Abciximab Therapy (from the PREDICT Trial)

American Journal of Cardiology

Volumn 101, Issue 6, 2008, Pages 796-800

  Kini, Annapoorna S ^a   Kim, Michael C ^a   Moreno, Pedro R ^a   Krishnan, Prakash ^a   Ivan, Oana C ^a   Sharma, Samin K ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE; C REACTIVE PROTEIN; CREATINE KINASE MB; RAPAMYCIN; TROPONIN I;

ADULT; AGED; ARTERY EMBOLISM; ARTICLE; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY FLOW RESERVE; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; FRACTIONAL FLOW RESERVE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROANGIOPATHY; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CORONARY CIRCULATION; CORONARY STENOSIS; CORONARY VESSELS; CREATINE KINASE, MB FORM; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; PROSPECTIVE STUDIES; STENTS; ULTRASONOGRAPHY, DOPPLER;

EID: 40049110282     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.053     Document Type: Article

References (15)

1. King H., Aubert R., and Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
2. Aronson D., Bloomgarden Z., and Rayfield E. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27 (1996) 528-535
3. Nahser P., Brown R., Oskarsson H., Winniford M.D., and Rossen J.D. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 91 (1995) 635-640
4. Akasaka T., Yoshida K., Hozumi T., Takagi T., Kaji S., Kawamoto T., Morioka S., and Yoshikawa J. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol 30 (1997) 935-941
5. Ragosta M., Samady H., Isaacs R., Gimple L.W., Sarembock I.J., and Powers E.R. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J 147 (2004) 1017-1023
6. Herrmann J., Haude M., Lerman A., Schulz R., Volbracht L., Ge J., Schmermund A., Wieneke H., Birgelen C., Eggebrecht H., Baumgart D., Heusch G., and Erbel R. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 103 (2001) 2339-2345
7. Albertal M., Voskuil M., Piek J.J., Bruyne B., Langenhove G., Kay P.I., Costa M.A., Boersma E., Beijsterveldt T., Sousa J.E., Belardi J.A., and Serruys P.W. Coronary flow velocity reserve after percutaneous interventions is predictive of Periprocedural outcome. Circulation 105 (2002) 1573-1578
8. Tschoepe D. The activated megakaryocyte-platelet system in vascular disease: focus on diabetes. Semin Thromb Hemost 21 (1995) 152-160
9. Neumann F.J., Blasini R., Schmitt C., Alt E., Dirschinger J., Gawaz M., Kastrati A., and Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
10. Lincoff M. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 107 (2003) 1556-1559
11. Marso S., Lincoff M., Ellis S., Bhatt D.L., Tanguay J.F., Kleiman N.S., Hammoud T., Booth J.E., Sapp S.K., and Topol E.J. Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 100 (1999) 2477-2484
12. Mathew V., Gersh B., Williams B., Laskey W.K., Willerson J.T., Tilbury R.T., Davis B.R., and Holmes D.R. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A Report From the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Circulation 109 (2004) 476-480
13. Haude M., Baumgart D., Welge D., Haude M., Baumgart D., Verna E., Piek J.J., Vrints C., Probst P., and Erbel R. Intracoronary doppler and quantitative coronary angiography-derived predictors of major adverse cardiac events after stent implantation. Circulation 103 (2001) 1212-1217
14. Marzilli M., Sambuceti G., Testa R., and Fedele S. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol 40 (2002) 2102-2109
15. Tomai F., Ribichini F., Ghini A., Ferrero V., Andò G., Vassanelli C., Romeo F., Crea F., and Chiariello L. Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur Heart J 26 (2005) 2099-2105